Almost two years ago, I posted information regarding a new FDA-approved drug for schizophrenia. (I believe it was Cobenfy)
It took everyone here by surprise because we all believed that 3-71 was going to be the first one to be approved. No one here had taken the time to research other competitors in the Schizo field. (Bourbon, in particular, was extremely pissed off...chalking it up to another lost opportunity due to Missling's glacial pace)
In any event, it shows the importance of being aware of your competitors or you're going to be left behind holding a bag of devalued stock.
So, based on Jim Cramer's comment: "The first one with a pill, wins!"...I feel obligated to inform you that there is another competitor that has a once-per-day oral pill to treat AD.
Some of you may already know about Annovis Bio...but for those of you that don't, it's important that you understand how close they are to getting approved by the FDA. Once that happens, your investment here in Anavex may dwindle to peanuts.
Here's what you need to know...
Annovis Bio started recruiting for their pivotal P3 AD trial in February, 2025. They are 90% complete in their enrollment (n=760). Yes. It's taken them 1 1/2 years to get to this point!
There are two markets in the AD field. Symptomatic = $7 Billion...and Disease Modifying = $100 Billion
Annovis Bio will be filing an NDA for both markets.
I strongly suggest that you watch the H.C. Wainwright video from 2025. https://www.annovisbio.com/video-library (Pay close attention especially at the 7-minute mark)
Don't ignore this information because it is a direct competitor to Anavex.
Market Data 
Markets 
